Phase III study

NRD103JP

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221589

Enrollment

480

Registered

2011-09-20

Start date

2011-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enthesopathy(lateral epicondylitis, patellar tendinosis, insertional achilles tendinosis, plantar fasciitis)

Interventions

investigational material(s) Generic name etc : Sodium Hyaluronate INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for I

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients diagnosed enthesopathy

Exclusion criteria

Exclusion criteria: -local injection or steroid topical treatment within 2 weeks from the first administration -Patient who has acute symptom on lesion area from operation on injury or sprain or fracture -Patient who has risk of infection by test drug injection

Design outcomes

Primary

Measure	Time frame
VAS To evaluate the change of VAS	—

Secondary

Measure	Time frame
Roles and Maudsley score, Local pain symptom, ADL assessment To evaluate the change and transition of each parameter	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026